- Home
- BKSY vs XERS Comparison
BKSY vs XERS Comparison
Compare BKSY & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BKSY | XERS |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | United States | United States |
| Employees | 321 | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | BKSY | XERS |
|---|---|---|
| Price | $27.69 | $8.23 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $28.50 | $10.83 |
| AVG Volume (30 Days) | 2.1M | ★ 2.2M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | ★ 0.01 |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | $27.03 | $34.37 |
| Revenue Next Year | $29.21 | $22.86 |
| P/E Ratio | ★ N/A | $828.00 |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $12.41 | $4.62 |
| 52 Week High | $52.88 | $10.08 |
Technical Indicators
Market Signals| Indicator | BKSY | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 41.22 | 83.52 |
| Support Level | $18.23 | $6.86 |
| Resistance Level | $29.63 | $8.46 |
| Average True Range (ATR) | 2.59 | 0.26 |
| MACD | 0.08 | 0.12 |
| Stochastic Oscillator | 35.27 | 94.19 |
Price Performance
Historical ComparisonAbout BKSY BlackSky Technology Inc.
BlackSky Technology Inc is a space-based technology company that delivers real-time imagery, analytics and high-frequency monitoring of the worlds critical and strategic locations, economic assets, and events. By taking a software-first technology approach, Company is delivering real-time space-based intelligence at disruptive speed, scale and economics. Companies single operating and reportable segment, provided space-based intelligence products and services through three integrated revenue streams-space-based intelligence & AI services, mission solutions, and technology programs. Geographically, the company operates in United States and Rest of world.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.